Device Glaucoma

Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3

Payments companies reported to CMS as associated with Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$41Kassociated payments (2023-2025)
464clinicians with associated payments
1company reporting

By year

2023 $41K

Payments reported as associated with Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Ophthalmology $31K
Optometrist $5,971
Glaucoma Specialist $2,755
Cornea and External Diseases Specialist $808
Retina Specialist $379
Neuro-Ophthalmology $148

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3

These are the largest totals companies reported as associated with Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Afshin Khodabakhsh Beverly Hills, CA Ophthalmology $531.61
Jillian Chong Beverly Hills, CA Cornea and External Diseases Specialist $490.05
David Hamilton Los Angeles, CA Ophthalmology $490.04
Alison Granier Coeur D Alene, ID Ophthalmology $358.30
Nicole Fuerst West Covina, CA Ophthalmology $327.11
David Fuerst West Covina, CA Ophthalmology $327.10
Alexander Knezevic Los Angeles, CA Ophthalmology $326.94
Arjan Hura Los Angeles, CA Ophthalmology $326.94
Majid Moarefi Long Beach, CA Ophthalmology $326.94
Eduardo Besser Culver City, CA Ophthalmology $326.94

Prescribed Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.